Scholar Rock Holding Corp
NASDAQ:SRRK

Watchlist Manager
Scholar Rock Holding Corp Logo
Scholar Rock Holding Corp
NASDAQ:SRRK
Watchlist
Price: 41.67 USD -5.79%
Market Cap: 4.3B USD
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of SRRK.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SRRK Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
24
Median 3Y
0
Median 5Y
0
Industry
8
Forward
20 056.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-7.2
Industry
23.5
Forward
-11.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-7.9
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-7.6
Industry
24.3
More Details
16.9
P/B
P/B
Price to Book Value
16.9
vs History
7
vs Industry
1
Median 3Y
6.3
Median 5Y
5
Industry
3.2
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
22
Median 3Y
0
Median 5Y
0
Industry
8.1
Forward
18 746.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.5
Industry
5.9
Forward
-9.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-5.4
Industry
6.2
Forward
-9.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-6.2
Industry
7.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-6.2
Industry
6.3
More Details
109.3
EV/IC
EV/IC
Enterprise Value to IC
109.3
vs History
7
vs Industry
3
Median 3Y
34.8
Median 5Y
17.7
Industry
5.6
More Details

Multiples Across Competitors

SRRK Competitors Multiples
Scholar Rock Holding Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Scholar Rock Holding Corp
NASDAQ:SRRK
4.1B USD 0 -11.7 -10.7 -10.7
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 120 668.6 -17 520 045.9 -17 192 530.1 -17 154 260
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 036 074.3 -161 768.4 -196 438.5 -194 196.9
US
Abbvie Inc
NYSE:ABBV
394.5B USD 6.6 168.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
177.2B USD 4.9 25.3 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
149.1B USD 5.1 18.4 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 10.2 32.7 24.1 25.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 069.8 -528.2 -575.1 -559.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
85.2B USD 6 18.7 17.8 20.2
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.7B USD 16.7 1 229.1 166.4 201.8
P/S Multiple
Revenue Growth P/S to Growth
US
Scholar Rock Holding Corp
NASDAQ:SRRK
Average P/S: 28 915 886.6
Not Available 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 120 668.6
140%
1 822 290.5
FR
Pharnext SCA
OTC:PNEXF
34 036 074.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 069.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
6
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
US
Scholar Rock Holding Corp
NASDAQ:SRRK
Average P/E: 216
Negative Multiple: -11.7 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 520 045.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 768.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
10%
1.9
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Scholar Rock Holding Corp
NASDAQ:SRRK
Average EV/EBITDA: 38.3
Negative Multiple: -10.7 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 192 530.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 438.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
166.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Scholar Rock Holding Corp
NASDAQ:SRRK
Average EV/EBIT: 45.2
Negative Multiple: -10.7 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 154 260 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 196.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.2
13%
1.6
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.8
N/A N/A

See Also

Summary
SRRK intrinsic value, competitors valuation, and company profile.
DCF Valuation
SRRK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SRRK stock valuation using valuation multiples.
Wall Street Estimates
SRRK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SRRK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.